Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease

Current Opinion in Lipidology

Volumn 14, Issue 4, 2003, Pages 347-352

  Caslake, Muriel J ^a   Packard, Chris J ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Atherosclerosis; HDL; Inflammation; LDL; Oxidized lipoproteins

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; C REACTIVE PROTEIN; CYTOKINE; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MATRIX METALLOPROTEINASE; PHOSPHOLIPASE A2;

AGING; ANIMAL MODEL; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; ENZYME ACTIVITY; FEMALE; GENE MUTATION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STROKE;

ANIMALS; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CLINICAL TRIALS; HUMANS; PHOSPHOLIPASES A; PLATELET ACTIVATION; RISK FACTORS;

ANIMALIA;

EID: 0042125177     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200308000-00002     Document Type: Review

References (49)

1. Skalen K, Gustafsson M, Knutsen Rydbery E, et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002; 417:750-754. An excellent test of the response-to-retention hypothesis providing conclusive data that subendothelial retention of apoB-100-containing lipoproteins is an early step in atherogenesis. The authors show that LDL (prepared by site-directed mutagenesis) in which proteoglycan binding is defective is considerably less atherogenic than its native counterpart.
2. Weijun J, Marchardier D, Rader DJ. Lipases and HDL metabolism. Trends Endocrin Metab 2002; 13:174-178.
3. 2 in vascular disease. Circ Res 2001; 89:298-304.
4. Jaross W, Eckey R, Menschikowski M. Biological effects of secretory phospholipase A2 group IIA on lipoproteins and in atherogenesis. Eur J Clin Invest 2002; 32:383-393.
5. Stafforini DM, McIntyre TM, Zimmerman GA, et al. Platelet-activating factor acetylhydrolases. J Biol Chem 1997; 18:17895-17898.
6. 2 in animal models and in humans. It discusses the potential atherogenic and antiatherogenic properties of the enzyme.
7. Stafforini DM, Elstad MR, McIntyre TM, et al. Human macrophages secrete platelet-activating factor acetylhydrolase. J Biol Chem 1990; 265:9682-9687.
8. Asano K, Okamoto S, Fukunaga K, et al. Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma. Biochem Biophys Res Commun 1999; 261:511-514.
9. 2 as a potential risk factor and a therapeutic target.
10. Stafforini DM, Satoh K, Atkinson DL, et al. Platelet-activating factor acetylhydrolase deficiency: a missense mutation near the active site of an anti-inflammatory phospholipase. J Clin Invest 1996; 97:2784-2791.
11. Cao Y, Stafforini DM, Zimmerman GA, et al. Expression of plasma activating-factor acetylhydrolase is transcriptionally regulated by mediators of inflammation. J Biol Chem 1998; 273:4012-4020.
12. 2, as an independent predictor of coronary heart disease. N Eng J Med 2000; 343:1148-1155.
13. 2, predict coronary events in patients with coronary artery disease. Circulation 1999; 100:1280-1284.
14. Memon RA, Fuller J, Moser AH, et al. In vivo regulation of plasma-activating factor acetylhydrolase during the acute phase response. Am J Physiol Integr Comp Physiol 1999; 277:R94-R103.
15. 2, platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1999; 19:2909-2917.
16. Caslake MJ, Packard CJ, Suckling KE, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 2000; 150:413-419.
17. 2 activity.
18. Stafforini DM, Tjoelker LW, McCormick SPA, et al. Molecular basis of the interaction between plasma platelet-activating factor and low density lipoprotein. J Biol Chem 1999; 274:7018-7024.
19. 2 levels and the risk of future cardiovascular events in women. J Am Coll Cardiol 2001; 38:1302-1306.
20. Karabina SAP, Liapikos TA, Grekas G, et al. Distribution of PAF-acetylhydrolase activity in human plasma low-density lipoprotein subtractions. Biochim Biophys Acta 1994; 1213:34-38.
21. Tselepis AD, Karabina SAP, Stengel D, et al. N-linked glycosylation of macrophage-derived PAF-AH is a major determinant of enzyme association with plasma HDL. J Lipid Res 2001; 42:1645-1654.
22. Marathe GK, Zimmerman GA, McIntyre TM. Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidised phospholipid hydrolase of high density lipoprotein particle. J Biol Chem 2003; 278:3937-3947.
23. Boisfer E, Stengel D, Pastier D, et al. Antioxidant properties of HDL in transgenic mice overexpressing human apolipoprotein A-II. J Lipid Res 2002; 43:732-741.
24. Forte TM, Subbanagounder G, Berliner JA, et al. Altered activities of anti-atherogenic enzymes LCAT, paraoxonase, and platelet-activating factor acetylhydrolase in atherosclerosis-susceptible mice. J Lipid Res 2002; 43:477-485.
25. 2 is associated solely with HDL, it is seen that the enzyme acts as an antiatherogenic factor. Enzyme was introduced by electroporation into the skeletal muscle of apoE deficient mice. Activity was increased up to 2.5-fold and the mean thickness of the artery wall decreased significantly.
26. -/- mice. FASEB J 2000; 14:2032-2039.
27. 2 inhibitor, in WHHL rabbits [abstract]. Atherosclerosis 2000; 151:166.
28. Macphee CH, Moores KE, Boyd HF, et al. Lipoprotein-associated A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 1999; 338:479-487.
29. 2 by specific inhibitors. The agents did not prevent LDL oxidation but diminished ensuing toxicity and induction of aptosis in macrophages. The inhibitor prevented the rise in lysophosphatidylcholine levels, which contributed to the cytonic effects of oxidized LDL.
30. 2-dependent manner. FEBS Lett 2000; 471:34-38.
31. Kume N, Cybulsky MI, Gimbrone MA Jr. Lysophosphatidylcholine, a component of atherogenic lipoproteins induces mononuclear leukocyte adhesion molecules in cultured and rabbit arterial endothelial cells. J Clin Invest 1992; 90:1138-1144.
32. Miwa M, Miyaket T, Yamanaka T, et al. Characterisation of serum platelet-activating factor (PAF) acetylhydrolase: correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children. J Clin Invest 1988; 82:1891-1893.
33. Stafforini DM, Satouk, Akkinson DL, et al. Platelet-activating factor acetylhydrolase deficiency, a missense mutation near the active site of an anti-inflammatory phospholipase. J Clin Invest 1996; 97:2784-2791.
34. Balta G, Gurgey A, Kudsuarov DK, et al. Evidence for the existence of the PAF acetylhydrolase mutation in non-Japanese populations: a preliminary study in Turkey, Azerbayan and Kyrgystan. Thromb Res 2001; 101:231-234.
35. Hiramoto M, Yoshida H, Imaizumi T, et al. A mutation in plasma platelet-activating factor acetylhydrolase (Val 279-Phe) is a genetic factor for stroke. Stroke 1997; 28:2417-2420.
36. Yamada Y, Ichihara S, Fujimura T, et al. Identification of the G994 → T missense mutation in exon 9 of the plasma platelet-activating factor acetylhydrolase gene is an independent risk factor for coronary artery disease in Japanese men. Metabolism 1998; 47:177-181.
37. Yamada Y, Yoshida H, Ichihara S, et al. Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population. Atherosclerosis 2000; 150:209-216.
38. Unno N, Nakamura T, Kaneko H. Plasma platelet-activating factor acetylhydrolase deficiency is a genetic risk factor for atherosclerotic occlusive disease in Japan. J Vasc Surg 2000; 32:263-267.
39. Unno N, Nakamura T, Mitsuoka H, et al. Association of a G994 → T missense mutation in the plasma platelet-activating factor acetylhydrolase gene with risk of abdominal aortic aneurysm in Japanese. Ann Surg 2001; 235:297-302.
40. Unno N, Nakamura T, Mitsuoka H, et al. Single nucleotide polymorphism (G994 → T) in the plasma platelet-activating factor-acetylhydrolase gene is associated with graft patency of femoropopliteal bypass. Surgery 2002; 132:66-71.
41. Yamamoto I, Fujitsu J, Nohnen S, et al. Association of plasma PAF acetylhydrolase gene polymorphism with IMT of carotid arteries in Japanese type 2 diabetic patients. Diabetes Res Clin Pract 2003; 59:219-224.
42. Dada N, Kim NK, Wolfert RL. Lp-PLA2: an emerging biomarker of coronary heart disease. Expert Rev Mol Diagn 2002; 2:89-94.
43. 2, high sensitivity c-reactive protein and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study. Chicago: American College of Cardiology, 2003. pp. 421-427.
44. Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B and HDL density subfractions. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001; 104:1108-1113.
45. Milochevitch C, Khalil A. Study of the paraoxonase and platelet-activating factor acetylhydrolase activities with aging. Prostaglandins Leukot Essent Fatty Acids 2001; 65:241-246.
46. Kosaka T, Yamaguchi M, Miyanaga K, et al. Serum platelet-activating factor acetylhydrolase (PAF-AH) activity in more than 3000 healthy Japanese. Clin Chim Acta 2001; 312:179-183.
47. Tsimihodimos V, Karabina SAP, Tambaki A, et al. Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler Thromb Vasc Biol 2002; 22:306-311.
48. Tsimihodimos V, Kakafika A, Afroditi P, et al. Fenofibrate induces HDL-associated PAF-acetylhydrolase but attentuates enzyme activity associated with apo-B containing lipoproteins. J Lipid Res 2003; 44:927-934.
49. 2: a target directed at the atherosclerotic plaque. Expert Opin Ther Targets 2002; 6:309-314.